References
- Left M, Avellaneda A, Bel Prieto A, et al. Enfermedades raras. un enfoque práctico. Instituto de Investigación de Enfermedades Raras del Instituto de Salud Carlos III. España: Ministerio de Sanidad and Consumo, 2004
- Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
- Cervantes F, Alvarez-Larran A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability. Presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-90
- Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 2010;16:358-67
- Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy. Safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a meann 2-year follow-up of COMFORT-I. Haematologica 2013; 98:1865-71
- Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitortreatment with ruxolitinib. Haematologica 2013;98:1872-6
- Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized. double-blind placebo controlled-trial. J Clin Oncol 2013;31:1285-92
- Price GL, Pohl GH, Xie J, et al. A retrospective observational study of annual healthcare costs for patients with forms of myeloproliferative neoplasms (MPN). 53rd ASH Annual Meeting and Exposition (abstract # 2060) American Society of Hematology. San Diego, CA; December 2011
- El Ouagari K, Knight CJ, Mendelson E. Cost-effectiveness of ruxolitinib versus best available therapy for medical treatment of the myelofibrosis: societal perspective. Poster at 54th ASH Annual Meeting and Exposition. Atlanta; December 2012
- Oliva J, Vilaplana C, Osuna R. El valor de los cuidados informales prestados en España a personas en situacion de dependencia. Instituto de Estudios Fiscales, 2011. Available at: http://www.ief.es/documentos/investigacion/seminarios/economia_publica/2011_11Julio.pdf
- Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7
- IMSERSO. Las personas mayores en España. Datos estadisticos estatales y por Comunidades Autonomas. Informe 2008/Tomo II. Colección Documentos. Serie Documentos Estadísticos. Spain: Ministerio de Sanidad and Politica Social
- Oliva J. Osuna R. Costs of the informal care en Spain. Presupuesto y Gasto Público 2009;56:163-81
- Mesa R, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-203
- Gimenez E, Rovira J, Gonzalez JD, et al. Diez años de umbral coste-efectividad. Farm Hosp 2013;37:85-7
- Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS. CHE Research Paper 60. York: University of York, 2011
- London School of Economics. Madrid: Work presented at Forum “Diálogo en Diabetes-Madrid 2013”
- Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503